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Abstract
Single nucleotide polymorphisms (SNPs) in TMEM106B encoding
the lysosomal type II transmembrane protein 106B increase the
risk for frontotemporal lobar degeneration (FTLD) of GRN (progran-
ulin gene) mutation carriers. Currently, it is unclear if progranulin
(PGRN) and TMEM106B are synergistically linked and if a gain or a
loss of function of TMEM106B is responsible for the increased
disease risk of patients with GRN haploinsufficiency. We therefore
compare behavioral abnormalities, gene expression patterns,
lysosomal activity, and TDP-43 pathology in single and double
knockout animals. Grn//Tmem106b/ mice show a strongly
reduced life span and massive motor deficits. Gene expression
analysis reveals an upregulation of molecular signature character-
istic for disease-associated microglia and autophagy. Dysregulation
of maturation of lysosomal proteins as well as an accumulation of
ubiquitinated proteins and widespread p62 deposition suggest
that proteostasis is impaired. Moreover, while single Grn/
knockouts only occasionally show TDP-43 pathology, the double
knockout mice exhibit deposition of phosphorylated TDP-43. Thus,
a loss of function of TMEM106B may enhance the risk for
GRN-associated FTLD by reduced protein turnover in the
lysosomal/autophagic system.
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Introduction
Frontotemporal lobar degeneration (FTLD) is the second most
common pre-senile neurodegenerative disease after Alzheimer’s
disease and is predominantly characterized by either tau or TAR
DNA-binding protein 43 (TDP-43) depositions. Clinically, FTLD-TDP
patients present with behavior and personality changes as well as
speech disabilities (Snowden et al, 2006). In addition, many patients
show an overlap with motor neuron diseases like amyotrophic
lateral sclerosis (ALS) (Hardy & Rogaeva, 2014). A strong family
history of dementia is present in FTD patients, implicating a signifi-
cant genetic component. C9orf72 repeat expansions (DeJesus-
Hernandez et al, 2011; Renton et al, 2011) and progranulin (PGRN)
haploinsufficiency are common causes of familial FTLD with TDP-
43 pathology (FTLD-TDP) (Baker et al, 2006; Cruts et al, 2006; Gass
et al, 2006). PGRN appears to exhibit neurotrophic and anti-inflam-
matory activities (Bateman et al, 2018). In addition, loss of PGRN is
linked to dysfunctional lysosomal degradation and autophagy
(Chang et al, 2017; Kao et al, 2017). While patients with PGRN
haploinsufficiency show lysosomal abnormalities and present with
some biochemical phenotypes of neuronal ceroid lipofuscinosis
(NCL) (Gotzl et al, 2014; Ward et al, 2017), homozygous mutations
leading to total loss of PGRN result in classical NCL (Smith et al,
2012; Almeida et al, 2016). PGRN is upregulated upon lysosomal
dysfunction (Capell et al, 2011) and co-regulated with other lysoso-
mal genes (Sardiello et al, 2009; Belcastro et al, 2011). Furthermore,
PGRN is transported to lysosomes (Hu et al, 2010; Zhou et al, 2015)
where it is processed by lysosomal proteases to granulin peptides
(Holler et al, 2017; Lee et al, 2017; Zhou et al, 2017b). Lysosomal
gene expression in Grn knockout mice is upregulated during aging
(Gotzl et al, 2014; Klein et al, 2017) or injury (Tanaka et al, 2013,
2017; Beel et al, 2017). In line with lysosomal dysfunction in GRN-
associated FTLD, aged Grn knockout mice are characterized by
accumulation of lipofuscin, saposin D, the autophagy markers
SQSTM1/p62 and ubiquitin. It is still puzzling that TDP-43
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pathology is abundant in GRN patients, but only occasionally
observed in aged Grn knockout mice (Ahmed et al, 2010; Yin et al,
2010a; Ghoshal et al, 2012; Petkau et al, 2012; Wils et al, 2012;
Gotzl et al, 2014; Tanaka et al, 2014).
The high variability in age of onset as well as the incomplete
penetrance of GRN mutations led to the search for genetic risk
factors in a genome-wide association study (GWAS), which identi-
fied single nucleotide polymorphisms (SNPs) in the TMEM106B
locus that segregate with GRN-associated FTLD (Van Deerlin et al,
2010). TMEM106B risk variants are also associated with C9orf72
repeat mutations (van Blitterswijk et al, 2014; Gallagher et al,
2014), TDP-43 pathology, severity of GRN independent FTLD, and
other neurodegenerative disorders (Rutherford et al, 2012; Murray
et al, 2014; Nelson et al, 2015; Yu et al, 2015). The most signifi-
cant SNPs are in high linkage disequilibrium with a SNP that leads
to a threonine to serine exchange at amino acid 185. The minor
protective S185 allele is underrepresented in FTLD and may thus
reduce the risk of GRN mutation carriers (Cruchaga et al, 2011;
Finch et al, 2011; van der Zee et al, 2011). However, contradictory
findings make it difficult to understand how TMEM106B and
PGRN functionally interact to increase the risk for FTLD-TDP.
There is some evidence that the risk haplotype enhances
inflammatory gene expression (Rhinn & Abeliovich, 2017; Ren
et al, 2018), whereas the protective variant provides neuroprotec-
tion (Li et al, 2020). Functionally, TMEM106B is linked to the
lysosomal protein degradation pathway and autophagy suggesting
an interaction with similar functions of PGRN. TMEM106B is an
endo-lysosomal type 2 transmembrane protein and plays a crucial
role in regulating lysosomal size, morphology, subcellular traf-
ficking, and acidification (Chen-Plotkin et al, 2012; Lang et al,
2012; Brady et al, 2013; Schwenk et al, 2014; Stagi et al, 2014). In
neurons, TMEM106B overexpression leads to enlarged lysosomes,
inhibits their acidification and transport, and results in accumula-
tion of LAMP1-positive structures at the cell soma (Stagi et al,
2014). This may be in line with increased mRNA and protein
levels (Van Deerlin et al, 2010; Nicholson et al, 2013; Gallagher
et al, 2017) in FTLD-TDP patients (Van Deerlin et al, 2010; Chen-
Plotkin et al, 2012; Gotzl et al, 2014). This would also be consis-
tent with the observation that a Tmem106b knockout rescues lyso-
somal deficits in Grn knockout mice (Klein et al, 2017). However,
knockdown of TMEM106B also results in clustering of lysosomes
in nuclear proximity and enhanced retrograde transport in
dendrites (Schwenk et al, 2014; Clayton et al, 2018). Moreover,
similar to TMEM106B overexpression, TMEM106B deficiency in
mice also results in impaired lysosomal acidification and reduced
lysosomal enzyme activities (Klein et al, 2017; Arrant et al, 2018)
and altered axonal transport accompanied by accumulation of lipo-
fuscin and autophagosomes (Luningschror et al, 2020). Thus, it is
currently unclear if a loss or a gain of function contributes to the
elevated risk for FTLD.
To understand a potential pathological consequence and syner-
gistic effects of PGRN and TMEM106B loss of function, we investi-
gated single knockout and double knockout animals. Surprisingly,
we found that loss of TMEM106B strongly enhanced age-related
PGRN phenotypes resulting in robust TDP-43 pathology, early
lysosomal dysfunction accompanied by an accumulation of ubiqui-
tinated proteins, severe microgliosis/astrogliosis, and dramatically
reduced life span. This suggests that the TMEM106B risk alleles
may modulate GRN-associated FTLD via a loss-of-function
mechanism.
Results
Loss of PGRN and TMEM106B leads to early motor deficits
in mice
To understand the contribution of a loss of function of TMEM106B
to FTLD pathology, we generated Grn/Tmem106b double knockout
animals. The Tmem106b/ mouse line was generated by injection
of targeted ES cells (KOMP clone EPD0047_1_E02) into BALB/C
blastocysts. Germline transmission of the tm2a allele (Wtsi lacZ
genetrap “knockout first” cassette between exon3 and exon4) was
verified, and the mice were bred with constitutively Cre recombi-
nase expressing mice to delete exon 4 and generate the
Tmem106b/ (tm2b) founder generation (Fig 1A) (see also
(Luningschror et al, 2020)). Grn//Tmem106b/ mice were
generated by crossing Tmem106b/ mice with Grn/ mice (Kaya-
suga et al, 2007). All genotypes were verified by Western blotting
(Fig 1B). In contrast to the single knockout lines, double knockout
Grn//Tmem106b/ mice showed a reduced life expectancy.
According to animal welfare practices, we had to sacrifice these
mice at 16–18 weeks of age when they reached pre-defined endpoint
criteria. The hind-leg clasping reflex test revealed an overt pheno-
typic difference between 3-month-old Grn//Tmem106b/ mice
and single knockout littermates or wild-type (WT) mice. Grn//
Tmem106b/ mice showed sustained hind limb clasping associated
with trunk flexion while single knockout and WT mice held their
▸Figure 1. Early motor deficits in Grn//Tmem106b/ mice.A Schema of the mouse wild-type and mutant Tmem106b locus. The tm2a allele carries a LacZ-Neo selection cassette in intron 3 and a loxP-flanked exon 4. Upon Cre
recombinase expression in the germline, exon 4 is deleted and Tmem106b expression abolished (tm2b allele).
B Western blot analysis of total brain lysates of wild-type, Tmem106b/, Grn/ and Grn//Tmem106b/ mice using antibody 6F2 to detect TMEM106B. (4.5-month-
old mice with the given genotype; n = 3 biological replicates per genotype).
C Hind limb clasping test wild-type, Tmem106b/, Grn/, Grn+//Tmem106b/ and Grn//Tmem106b/ mice. Representative pictures are shown of three mice
analyzed for each genotype at 3 months of age.
D Rotarod performance of wild-type, Tmem106b/, Grn/, Grn+//Tmem106b/ and double knockout animals at 3–4 months of age. Number of animals used for
analysis, 10 wild-type, 12 Tmem106b/, five Grn/, seven Grn+//Tmem106b/, three Grn//Tmem106b/ mice.
E Representative picture of a 4.5-month-old double knockout (Grn//Tmem106b/) mouse after manual flip.
Data information: For statistical analysis (D), one-way ANOVA with Tukey’s post hoc test was used to compare the mean  SD of the individual genotypes. Significance is
indicated; *P < 0.05; **P < 0.01; and ****P < 0.0001.
Source data are available online for this figure.
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hind limbs apart with paw external rotation (Fig 1C). Furthermore,
the rotarod test confirmed motor incoordination in Grn//
Tmem106b/ mice (Fig 1D). The motor deficits of the Grn//
Tmem106b/ mice, visible by shaking-like movements and paresis
of hind limbs, increased with age to a stage in which the mice could
not turn back, when they were manually flipped over (Fig 1E and
Movie EV1). To investigate whether the total loss of TMEM106B
and PGRN is required for developing such a strong phenotype, we
analyzed Grn/+/Tmem106b/ mice. Although the hind-leg clasp-
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their back, rotarod performance was significantly impaired
compared to WT but significantly improved compared to double
knockout mice (Fig 1D). Thus, reduced PGRN levels in combination
with TMEM106B loss of function exacerbate the rather mild pheno-
types of the individual knockouts. However, the strong effect on life
expectancy only occurred upon total loss of both proteins PGRN and
TMEM106B.
Enhanced dysregulation of genes in the double knockout is
associated with microglia and astrocyte function
To specify functional changes in Grn//Tmem106b/ mice, we
analyzed the expression of genes associated with neurodegenera-
tive diseases using the nCounter Neuropathology panel (Nano-
String Technologies) in total brain of 4.5-month-old mice. Genes
expressed in neurons, astrocytes, microglia, oligodendrocytes, and
endothelial cells, addressing six fundamental themes of neurode-
generation including neurotransmission, neuron–glia interaction,
neuroplasticity, cell structure integrity, neuroinflammation, and
metabolism, were analyzed. Gene expression levels of 760 genes
in each sample were normalized against the geometric mean of
10 housekeeping genes. The most significant dysregulation of
genes was found in Grn//Tmem106b/ mice (Fig 2A–C).
While in single knockout mice expression of genes was altered
no more than two-fold up or 0.5-fold down, in the double knock-
out mice 23 genes were dysregulated above/below these values.
Overlap in gene expression was considered if a gene was signifi-
cantly changed in the respective mouse models with more than
20% change in at least one mouse model. Most overlap exists
between Tmem106b/ and Grn//Tmem106b/ mice (15
genes, 10 up, five down), while the strongest modulation occurs
in a gene cluster associated with activated microglia in Grn/
and Grn//Tmem106b/ mice (Cd68, C1qc) or in all three
mouse models (Trem2, C1qa, C1qb; Fig 2D). Notably, almost all
overlapping genes are regulated in the same direction. The double
knockout mice show the strongest effects, and the changes in
gene expression are not simply the additive effects of single
knockout mice (Fig 2D). In line with previous findings, pathway
analyses revealed upregulation of gene clusters associated with
activated microglia, autophagy (Lui et al, 2016; Gotzl et al, 2019),
and angiogenesis in Grn/ mice and in Tmem106b/ mice
(Fig 2E). Scores of these gene clusters were strongly elevated in
the double knockout animals (Fig 2E), suggesting severe
microgliosis and deficits in protein degradation. Moreover, all
downregulated genes in Grn//Tmem106b/ mice are associ-
ated with “axon and dendrite structure” and “neural connectiv-
ity”. The strongest downregulation in Grn//Tmem106b/ mice
was observed for genes affecting “myelination” (Fa2h, Mog, Mag,
Ugt8a, Mal; Fig 2C). Note that downregulation of myelination-
associated genes could be confirmed on the protein level
(Fig EV1). Interestingly, in several pathways associated with
neuronal function like “neuronal cytoskeleton”, “myelination”,
“axon and dendrite structure”, and “vesicle trafficking”, a high
score is only observed in double knockout mice, while single
knockout mice show no changes (Fig 2E).
Besides upregulated genes associated with hyperactivated micro-
glia, Gfap is 6.5-fold upregulated and therefore after Cd68, which is
eight-fold upregulated, the second strongest upregulated gene in the
double knockout mice (Fig 2C). Thus, we also addressed glial
pathology by analyzing gene expression using the nCounter
Neuroinflammation panel (NanoString Technologies) covering 757
genes and 13 housekeeping in total brain of 4.5-month-old mice.
Gene expression levels were analyzed as described for the nCoun-
ter Neuropathology panel. As expected expression changes in the
single knockout mice are low, no gene reaches a two-fold or 0.5-fold
change in expression (Fig 3A and B). The double knockout mice
show again the strongest effects with 27 genes either with a two-fold
or 0.5-fold change, and 126 genes with more than 20% change
(Fig 3C). Changes in gene expression are not simply additive
(Fig 3D). Ninteen genes were altered in all three mouse models and
17 genes altered in the double knockout together with either single
knockout (Fig 3D). As observed for the Neuropathology panel,
almost all overlapping genes are regulated in the same direction.
Downregulation overlapped only in Tmem106b/ and Grn//
Tmem106b/ mice, while upregulation overlapped more between
Grn/ and Grn//Tmem106b/ mice in astrocytic and microglial
expressed genes (Fig 3D). Furthermore, all inflammation-associated
pathways, like “innate and adaptive”, “immune response”, “inflamma-
tory signaling”, and “astrocyte and microglia function”, were slightly
upregulated in Grn/ mice and strongly increased in Grn//
Tmem106b/ mice (Fig 3E). Thus, the hyperactivated microglial state
identified in the Neuropathology panel was confirmed with the
Neuroinflammation panel. In line with expression changes of genes
associated with myelination, detected in the Neuropathology panel,
▸Figure 2. Expression analysis reveals global dysregulation of gene clusters associated with autophagy and microglial activation in double knockout mice.A–C Volcano plot of differentially expressed brain mRNAs of 4.5-month-old mice (n = 3 biological replicates per genotype) detected by the Neuropathology panel
of NanoString. Expression changes were only taken into consideration when the extent of change was above 20% as indicated by vertical lines for all
volcano plots. Gliosis- and myelination-related genes are highlighted if changes are above 20%. Fold changes are displayed after log2 transformation. (A)
Comparison of differentially expressed brain mRNAs from Tmem106b/ and wild-type mice. From 680 detected genes, 21 are significantly upregulated, while
10 are significantly reduced. (B) Comparison of Grn/ and wild-type mice. From 680 detected genes, 12 are significantly upregulated, while six are
significantly reduced. (C) Volcano plot for Grn//Tmem106b/ and wild-type mice. From 680 detected genes, 79 are significantly upregulated, while 24 are
significantly reduced.
D Display of differently expressed genes overlapping between the analyzed genotypes from (A–C). Overlap was considered if a gene was significantly changed in the
respective mouse models with more than 20% change in at least one mouse model. Note that nine genes are significantly altered in all three genotypes in
comparison to the wild type. Seven genes are exclusively overlapping between the Grn/ and the Grn//Tmem106b/ mice. Tmem106b/ and Grn//
Tmem106b/ mice share 15 significantly altered genes. Tmem106b/ and Grn/ mice share one significant altered gene. Data represent the mean  SD.
E Gene set analysis based on NanoString advanced analysis R-script included in the Neuropathology panel.
Data information: For statistical analysis of volcano plot data, unpaired two-tailed Student’s t-test was performed between individual genotypes and the wild-type
control condition. Significance was accepted when P < 0.05 as indicated by the dotted line.
Source data are available online for this figure.
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“oligodendrocyte function” is also strongly reduced in the double
knockout (Fig 3E).
Exaggerated gliosis in young Grn//Tmem106b/ mice
To validate the changes of the mRNA signature at the protein level, we
performed biochemical analyses of total brain homogenate from 4.5-
month-old mice. This confirmed a significant 3.4- to 4.7-fold increase
of GFAP and IBA1 expression in Grn//Tmem106b/ mice (Fig 4A
and B) which is in line with strong astrogliosis and microgliosis in the
double knockout. Importantly and consistent with our previous find-
ings in Grn/ mice (Gotzl et al, 2014), at this age no microgliosis and
astrogliosis was apparent in the single knockouts (Fig 4A and B).
Next, we investigated by immunohistochemistry which brain regions
were particularly affected by gliosis. Astrogliosis and microgliosis were
most prominent in the thalamus, pons and medulla, midbrain, cerebel-
lum, and cerebral cortex of the double knockout mice (Figs 4C and D,
and EV2A and B). To confirm enhanced microgliosis in double knock-
out mice in vivo, we performed previously established TSPO-lPET
(Brendel et al, 2016; Gotzl et al, 2019). A higher increase of TSPO
signals between 2- and 3.5-month-old Grn//Tmem106b/ mice
compared to WT was detected in the regions of accelerated astro- and
microgliosis, like thalamus, pons and medulla, midbrain, and cerebel-
lum (Fig 4E). To further investigate microglial activation in the dif-
ferent mouse lines, we analyzed protein expression of CD68, CLEC7A,
TREM2, and ApoE in total brain extracts of 4.5-month-old mice
(Fig 5A). Quantification revealed a significant increase of all four
proteins in Grn//Tmem106b/ mice (Fig 5B). Only TREM2 was
also significantly elevated in Grn/ mice (Fig 5B). In Grn//
Tmem106b/ mice, most IBA1-positive microglia are also positive for
CLEC7A, CD68, and to a lower extent for TREM2 confirming activated
microglia already at the age of 4.5 months (Fig 5C–E).
The strong motor phenotype together with the gliosis in regions
of the brainstem let us additionally analyze the spinal cord for
astrogliosis and microgliosis. Again, only Grn//Tmem106b/
mice show a strongly increased expression of GFAP and CD68, a
microglial lysosomal membrane protein, in both white and gray
matter (Fig EV3).
Enhanced lysosomal and autophagic dysfunction in Grn//
Tmem106b/ mice
Activation of microglia is accompanied by elevated expression of
lysosomal cathepsins, which was described for aged Grn/ mice
(Ahmed et al, 2010; Wils et al, 2012; Tanaka et al, 2013; Gotzl et al,
2014; Klein et al, 2017). In line with these observations, Grn//
Tmem106b/ mice show elevated levels of the cathepsin D, cathep-
sin B, and cathepsin L compared to WT and single knockout mice
(Fig 6A and B). The elevated CatD and CatL expression levels result
in significantly increased enzymatic activities compared to WT and
single knockout mice (Fig 6C). Elevated lysosomal protease expres-
sion and lysosomal activity often indicate impaired protein degrada-
tion and accumulation of autophagy cargo as observed in NCL
mouse models (Gotzl et al, 2014) and in aged Grn knockout mice
(Ahmed et al, 2010; Wils et al, 2012; Gotzl et al, 2014). Further-
more, autophagy is among the strongest hits in the pathway analysis
◀ Figure 3. Expression analysis reveals enhanced dysregulation of genes associated with microglia and astrocyte function.A–C Analysis of brain mRNA expression of 4.5-month-old mice (five wild-type, four Grn/, four Tmem106b/, five Grn//Tmem106b/ mice) detected by the
Neuroinflammation panel by NanoString. Expression changes were only taken into consideration when the extent of change was above 20% as indicated by
vertical lines for in all volcano plots. Gliosis-related genes are highlighted if changes are above 20%. Fold changes are displayed after log2 transformation.
(A) Comparison of differentially expressed mRNA of Tmem106b/ mice in comparison to wild-type mice. From 622 detected genes, 21 are significantly upregulated,
while 12 are significantly reduced. (B) Comparison of differentially expressed mRNA in Grn/ and wild-type mice. From 622 detected genes, 32 are significantly
upregulated, while only one is significantly reduced. (C) Volcano plot of differentially expressed brain mRNAs from Grn//Tmem106b/ mice in comparison to
wild-type mice. From 622 detected genes, 110 are significantly upregulated, while 16 are significantly reduced.
D Display of differently expressed genes overlapping between the analyzed genotypes from (A–C). Overlap was considered if a gene was significantly changed in the
respective mouse models with more than 20% change in at least one mouse model. Note that 19 genes are significantly altered in all three genotypes in
comparison to the wild type. Seventeen genes are exclusively overlapping between the Grn/ and the Grn//Tmem106b/ mice. Tmem106b/ and Grn//
Tmem106b/ mice share 17 significantly altered genes. Data represent the mean  SD.
E Gene set analysis based on NanoString advanced analysis R-script included in the Neuroinflammation panel.
Data information: For statistical analysis of volcano plot data, unpaired two-tailed Student’s t-test was performed between individual genotypes and the wild-type
control condition. Significance was accepted when P < 0.05 as indicated by the dotted line.
Source data are available online for this figure.
▸Figure 4. Astrogliosis and microgliosis in different brain regions of Grn//Tmem106b/ mice.A Western blot analysis of GFAP and IBA1 in total brain lysates from 4.5-month-old mice with the given genotype (n = 3 biological replicates per genotype).
B Quantification of (A). Protein expression was normalized to levels in wild-type animals. Data represent the mean  SD.
C Expression of GFAP in sagittal brain sections. Representative images of indicated brain regions (CBX, cerebellum; CTX, cortex; MY, medulla; TH, thalamus). Scale bar
indicates 100 lm.
D Expression of IBA1 in sagittal brain sections. Representative images of indicated brain regions (CBX, cerebellum; CTX, cortex; MY, medulla; TH, thalamus). Scale bar
indicates 100 lm.
E In vivo 18F-GE180 TSPO lPET imaging. Two female Grn//Tmem106b/ and five female wild-type mice underwent longitudinal TSPO lPET at 2.0 and 3.5 months of
age. All analyses were performed by PMOD (V3.5, PMOD technologies). Normalization of injected activity was performed by the previously validated myocardium
correction method.
Data information: (B), one-way ANOVA with Tukey’s post hoc test was used to compare individual genotypes. Significance is indicated; ***P < 0.001; and ****P < 0.0001.
Source data are available online for this figure.
ª 2020 The Authors EMBO reports 21: e50241 | 2020 7 of 19
Georg Werner et al EMBO reports
of both NanoString panels (Figs 2E and 3E); therefore, we next
investigated accumulation of autophagic cargo. Since the complete
loss of PGRN results in a NCL-like storage phenotype with exagger-
ated deposition of lipofuscin in aged mice (Kleinberger et al, 2013),
we investigated the autofluorescence signal in single and double
knockout mice. Lipofuscin is detectable predominantly in the thala-
mus of the double knockout mice, while the single knockout mice
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4.5 months of age (Fig 7A). Interestingly, in Grn//Tmem106b/
mice lipofuscin accumulation partially overlaps with the microglia
marker IBA1, which may suggest early degradation deficits in micro-
glia (Fig 7A). Lipofuscin accumulation indicates a dysfunction in
protein degradation as described for NCL (Palmer et al, 2013) and
GRN-associated FTLD (Ward et al, 2017). Since protein aggregates
and long-lived proteins are normally cleared by autophagy, we
investigated the multifunctional adaptor protein p62/sequestosome1
(p62/SQSTM1), which directs ubiquitinated cargos for autophagy.
Indeed, Grn//Tmem106b/ mice show robustly elevated p62/
SQSTM1 levels in RIPA and urea lysates compared to single knock-
out and WT mice (Fig 7B and C). The accumulation of p62/SQSTM1
in the urea lysate reflects reduced solubility and indicates elevated
protein aggregation. Furthermore, p62/SQSTM1 accumulates in all
brain regions associated with elevated astrogliosis and microgliosis
of Grn//Tmem106b/ mice including the spinal cord (Figs 7D
and EV3). Co-staining of p62/SQSTM1 with NeuN, Iba1, or GFAP
shows that most p62/SQSTM1 accumulates in neurons and not in
microglia or astrocytes (Figs 7E and F). The minor co-localization of
p62 with microglia is also supported by little overlay in the cerebel-
lar staining (Fig EV4). In line with accumulation of the p62/
SQSTM1, ubiquitinated proteins are significantly increased and
autophagosomes are accumulated, as indicated by elevated LC3II
levels, in double knockout mice compared to single knockout mice
(Fig 7B and C).
Accelerated TDP-43 aggregation and phosphorylation in Grn//
Tmem106b/ mice
The pathological hallmarks of GRN-associated FTLD are nuclear and
cytoplasmic, ubiquitin positive inclusions composed of phosphory-
lated TDP-43 and its proteolytically generated C-terminal fragments.
In aged Grn knockout mice, cytoplasmic TDP-43 depositions were
only occasionally detected (Guo et al, 2010; Kleinberger et al, 2010;
Yin et al, 2010b). To address the question if the additional loss of
TMEM106B promotes TDP-43 pathology in the Grn knockout mice,
we performed immunohistochemistry. Small cytoplasmic TDP-43
inclusions were detected throughout the brain of Grn//
Tmem106b/ mice (Figs 8A and EV5). They were less frequent in
the cortex and most abundant in the midbrain (Fig 8A). Some of the
inclusions also contain TDP-43 phosphorylated at amino acids 409/
410, a specific hallmark of FTLD-TDP (Hasegawa et al, 2008;
Neumann et al, 2009) (Fig 8B). Sequential high salt (HS), RIPA, and
urea extraction of total brain homogenate revealed slightly reduced
levels of TDP-43 holoprotein in the HS fraction of the Grn//
Tmem106b/ mice compared to WT and Tmem106b/ mice
(Fig 8C and D), but elevated levels of a RIPA-extracted C-terminal
TDP-43 fragments of approximately 35 kDa (Fig 8C and D). Moreover,
phosphorylated TDP-43, specifically detected in the urea fraction, is
significantly elevated in the double knockout mice (Fig 8C and D).
Discussion
In this study, we demonstrate that the combined knockout of
Tmem106b and Grn accelerates the phenotypes of the individual
knockout mice suggesting that a loss of function of TMEM106B
further promotes Grn-associated FTLD.
Motor impairment is an early and very prominent phenotype
detected in Grn//Tmem106b/ mice and to a much lesser extent in
Grn+//Tmem106b/ mice already at 3 months of age (Fig 1C–E).
Hind limb clasping and paralysis has been observed in a number of
mouse models for neurodegenerative diseases like Alzheimer’s
disease, Parkinson’s disease, and other tauopathies (http://www.inf
◀ Figure 5. Enhanced expression of proteins associated with activated microglia in Grn//Tmem106b/ mice.A Western blot analysis of CD68, CLEC7A, TREM2, and ApoE in total brain lysates from 4.5-month-old mice with the given genotype. Asterisk indicates unspecific band
(n = 3 biological replicates per genotype).
B Quantification of (A). Protein expression was normalized to levels in wild-type animals. Data represent the mean  SD.
C Expression of CD68 and the microglial marker IBA1 in sagittal brain sections. Representative images of indicated brain regions (TH, thalamus). Scale bar indicates
25 lm.
D Expression of CLEC7A and the microglial marker IBA1 in sagittal brain sections. Representative images of indicated brain regions (MY, medulla). Scale bar indicates
25 lm.
E Expression of TREM2 and the microglial marker IBA1 in sagittal brain sections. Representative images of indicated brain regions (MY, medulla). Scale bar indicates
25 lm.
Data information: For statistical analysis of protein levels (B), one-way ANOVA with Tukey’s post hoc test was used to compare individual genotypes. Significance is
indicated; *P < 0.05; **P < 0.01; ***P < 0.001; and ****P < 0.0001.
Source data are available online for this figure.
▸Figure 6. Elevated lysosomal enzyme levels and activity in Grn//Tmem106b/ mice.A Western blot analysis of cathepsin (Cat) D, B, and L in total brain lysates from 4.5-month-old mice with the indicated genotype. Different maturation variants are
indicated (hc, heavy chain; p, preform; sc, single chain; n = 3 biological replicates per genotype).
B Quantification of proteolytically generated variants of cathepsin D, B, and L normalized to levels in wild-type animals from (A). Data represent the mean  SD.
C Catalytic activity of cathepsin D, B, and L. Total brain lysates from 4.5-month-old mice were incubated with quenched fluorogenic substrate for Cat D, Cat B, and Cat
L. The linear increase of fluorescence signal was measured and then normalized to wild type. Data represent the mean normalized activity  SD (n = 3 biological
replicates per genotype).
Data information: For statistical analysis of normalized data (B, C), one-way ANOVA with Tukey’s post hoc test was used to compare individual genotypes. Significance is
indicated; ns P > 0.05; *P < 0.05; **P < 0.01; ***P < 0.001; and ****P < 0.0001.
Source data are available online for this figure.
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ormatics.jax.org/mp/annotations/MP:0001513) and may indicate
progression of neurodegeneration, including cerebellar ataxia. In
addition, several FTD/ALS mouse models (Wils et al, 2010; Le et al,
2016; Liu et al, 2016) as well as autophagy-related mouse models
(Komatsu et al, 2005; Hara et al, 2006) present with similar motor
deficits. Impaired autophagy has been associated with many
neurodegenerative diseases (Nixon, 2013) including FTD/ALS (Gotzl
et al, 2016). In Tmem106b and Grn double knockout mice, dysfunc-
tion in the lysosomal/autophagic degradation is indicated by accu-
mulation of lipofuscin, ubiquitinated proteins, and the cargo adaptor
protein p62 (Fig 6A–E). P62 interacts with autophagic substrates and
delivers them to autophagosomes for degradation. Since p62 is also
degraded during this process, accumulation of p62 suggests that the
turnover of autophagosomes may be delayed which is also indicated
by LC3II accumulation. Elevated autophagy associated with an
increase of autophagosomes and cargo adaptor proteins is unlikely
since mRNA expression of autophagy initiating genes and cargo
adaptors is not elevated. However, we cannot distinguish between a
failure of autophagosome/lysosome fusion or lysosomal degradation
of engulfed autolysosome since both would result in cargo, p62 and
LC3II accumulation.
A significant contribution of dysfunctional autophagy to the
prominent phenotype of the double knockout mice is further
supported by “autophagy” being one of the strongest hits in the
pathway analysis of the nCounter Neuropathology gene expression
panel (Fig 2E). Indicators of impaired protein degradation are also
detected in single knockout mice, albeit to a much lesser extent. In
line with our earlier findings (Gotzl et al, 2018), “autophagy” was
also one of the strongest hits in the pathway analysis in Grn/ mice
(Fig 2E). Furthermore, in line with previous findings (Ahmed et al,
2010; Ghoshal et al, 2012; Wils et al, 2012; Petkau et al, 2016; Beel
et al, 2017; Tanaka et al, 2017; Zhou et al, 2017a; Gotzl et al, 2018)
Grn/ mice also showed impaired protein degradation but recog-
nizable effects occur after the age 6 months.
Besides PGRN, the lysosomal transmembrane protein
TMEM106B is linked to lysosomal integrity and function (Chen-
Plotkin et al, 2012; Lang et al, 2012; Brady et al, 2013; Schwenk
et al, 2014; Stagi et al, 2014). In cell culture, loss of TMEM106B
affects lysosomal positioning and trafficking (Schwenk et al, 2014;
Stagi et al, 2014) leading to reduced stress resistance (Stagi et al,
2014). However, overexpression also results in dysfunctional and
enlarged lysosomes (Chen-Plotkin et al, 2012; Brady et al, 2013;
Stagi et al, 2014) causing a translocation of the autophagy regula-
tion transcription factor EB (TFEB) to nuclei (Stagi et al, 2014).
Since such prominent phenotypes were detected in cellular systems,
it is surprising that some Tmem106b knockout mouse models
revealed only minor changes in lysosomal integrity (Klein et al,
2017; Arrant et al, 2018; Nicholson et al, 2018). We demonstrate
that 4.5-month-old Tmem106b knockout mice show ubiquitin accu-
mulation and few p62-positive inclusions in cortex and cerebellum
(Fig 6A and C). Additionally, it was recently demonstrated that
these mice show vacuolization in thalamus and facial motor nucleus
accompanied by large LAMP1-positive membrane structures (Lun-
ingschror et al, 2020). Mechanistically, this could be explained by
an enhanced retrograde axonal transport of lysosomes followed by
an accumulation of endo-/lysosomal membrane structures at the
axon initial segment, which may result in reduced fusion of lyso-
somes with autophagosomes. Reduced fusion may lead to impaired
autophagic degradation in Tmem106b mice (Luningschror et al,
2020). Therefore, the strong phenotype of the Grn//Tmem106b/
mice could be the consequence of disturbed lysosomal (Beel et al,
2017; Tanaka et al, 2017; Zhou et al, 2017a) and autophagic activities
(Chang et al, 2017) in neurons and microglia.
In clear contrast to our observations, additional loss of
TMEM106B has recently been reported to protect against the FTLD-
like phenotypes in Grn/ mice (Klein et al, 2017), while our find-
ings and those published independently by two other research
teams in this issue of EMBO Reports (Feng et al, 2020a; Zhou et al,
2020a) even demonstrate prominent gliosis, premature death, and
exacerbated FTLD-like pathology. Klein et al report an increase in
several lysosomal enzymes and their activity in 2-month-old Grn/
mice. These enhanced activities of lysosomal enzymes are reduced
upon additional TMEM106B knockout. However, lipofuscin accu-
mulation is not reduced, which indicates that dysfunction in protein
degradation is not improved. One may speculate that the elevated
lysosomal enzyme levels and activities in Grn/ mice, which
predominantly occur in non-microglial cells (Gotzl et al, 2018),
could be a rescue attempt in response to the lysosomal dysfunction.
Lysosomal dysfunction shows the strongest effects in microglia
since these cells have the highest PGRN expression (Lui et al, 2016;
Gotzl et al, 2018) and are the degradation hub in the brain. Thus,
with additional loss of TMEM106B the ability to upregulate such
rescue mechanisms may be lost or overcome by factors released
from malfunctional microglia. In line with the idea that TMEM106B
plays a role in regulating a lysosomal rescue mechanism, it has been
shown that TMEM106B knockdown reduces the signaling of TFEB
(Stagi et al, 2014), a master regulator of the lysosomal autophagic
pathway (Settembre & Ballabio, 2011; Settembre et al, 2011).
◀ Figure 7. Widespread impairment of autophagy and protein degradation in Grn//Tmem106b/ mice.A Immunofluorescence analysis of lipofuscin (red) and IBA1 (green) in sagittal brain sections. Representative images of the thalamus (TH). Scale bar indicates 25 lm.
B Western blot analysis of ubiquitin and the autophagy marker LC3 in RIPA, and p62 in RIPA and urea total brain lysates from 4.5-month-old mice with the indicated
genotype. Calnexin used as a loading control. (n = 3 biological replicates per genotype).
C Quantification of (B). Protein expression was normalized to levels in wild-type animals. Data represent the mean  SD.
D Immunofluorescence analysis of p62 in sagittal brain sections. Representative images of indicated brain regions (CBX, cerebellum; CTX, cortex; MY, medulla; TH,
thalamus). Scale bar indicates 100 lm.
E Localization of p62 mainly in NeuN-positive cells in the cortex (CTX) of 4.5-month-old mice. Minor overlap of aggregates with microglial marker IBA1. Scale bar
indicates 15 lm.
F Complete overlap of co-staining of p62 with NeuN in the cortex (CTX) and not with the reactive astrocyte marker GFAP. Scale bar indicates 15 lm.
Data information: For statistical analysis of normalized data (C), one-way ANOVA with Tukey’s post hoc test was used to compare individual genotypes. Significance is
indicated; ns P > 0.05; *P < 0.05; **P < 0.01; ***P < 0.001; and ****P < 0.0001.
Source data are available online for this figure.
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Loss of TMEM106B in Grn/ mice dramatically enhanced
astrogliosis and microgliosis (Fig 4). Note, that 7- to 18-month-old
Grn/ mice show similar progressive astrogliosis and microgliosis
(Ahmed et al, 2010; Yin et al, 2010b; Ghoshal et al, 2012; Petkau
et al, 2012; Wils et al, 2012) but the double knockout mice develop
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“activated microglia”, “innate and adaptive immune response”, “in-
flammatory signaling”, and “astrocyte function” are the strongest
hits in the gene expression pathway analysis (Figs 2E and 3E).
Several genes related to inflammation and disease-associated micro-
glia (DAM) are already slightly upregulated in the brain of Grn/
mice (Figs 2B and 3B) and further increased in Grn//
Tmem106b/ mice (Figs 2C and 3C). Of note, the double knockout
of Grn//Tmem106b/ shifts the change in the mRNA signature
to a much earlier time point as observed in Grn/ alone (Lui et al,
2016; Gotzl et al, 2019). Among the strongest hits in double knock-
outs are mostly microglial expressed genes such as Cd68, Trem2,
Tyrobp, Apoe, and complement factors but also genes associated
with astrocyte activation such as Gfap, Serpina3n, and C4a (Figs 2C
and 3C). Additionally, we detect in 4.5-month-old double knockouts
reduced gene expression of myelination-associated genes (Fa2h,
Mog, Mag, Ugt8a, Mal) and reduced protein levels of MOG and MAP
(Fig EV1) which is in line with recent publications describing myeli-
nation deficits upon TMEM106B deficiency or loss of function (Feng
et al, 2020b; Ikemoto et al, 2020; Zhou et al, 2020b).
Finally, the question arises how PGRN and TMEM106B defi-
ciency results in lysosomal dysfunction affecting mainly microglia,
which initiates autophagic cargo protein accumulation and patho-
logical TDP-43 deposition in neurons. Since PGRN is mainly
expressed in microglia, whereas TMEM106b is ubiquitously
expressed within the brain (with the lowest expression in micro-
glia), it is tempting to speculate that microglia lacking PGRN may
initiate a pathological crosstalk to neurons. Another option would
be that TMEM106B-deficient neurons required protective support
from microglia, which could not be provided upon additional PGRN
deficiency. In the same vein, malfunctioned oligodendrocytes may
not receive support in the absence of PGRN. These scenarios suggest
that dysfunctional microglia cannot appropriately communicate




All animal experiments were performed according to German
animal welfare law and approved by the government of upper
Bavaria. Mice were kept under standard housing conditions includ-
ing standard pellet food and water provided ad libitum.
Recombinant mouse ES cells carrying loxP sites flanking Exon 4 of
Tmem106b (tm2a allele) were provided by the KOMP consortium
(Clone EPD0047_1_E02). Blastocyst injection of the tm2a allele
carrying ES cells leads to chimeric mice that were further bread with
Cre deleter mice after germline transmission to obtain the
Tmem106b/ mouse line. The Grn/ mouse line was kindly
provided by Dr. M. Nishihara. Breeding and behavior tests were
performed under the animal license: ROB-55.2-2532.Vet_02-17-106.
Mice were perfused with PBS after deep/lethal anesthesia.
Rotarod behavior test
The rotarod test was conducted in accordance with European and
national guidelines, and all experiments were performed with the
researcher blinded to the genotype. The spindle speed was acceler-
ated from 5 to 50 rpm over 5 min. The test finished either when the
mouse dropped down or after the time limit of 5 min. After three
rounds of training on three individual days, the average time of
three trials with 1-h break in between was used.
In vivo lPET imaging
Small animal positron emission tomography (lPET) procedures
followed an established standardized protocol for radiochemistry,
acquisition, and post-processing (Brendel et al, 2016). In brief, 18F-
GE180 TSPO lPET with an emission window of 60–90 min post-
injection was used to measure cerebral microglial activity. Two
female Grn/ &Tmem106b/ and five female wild-type mice
underwent longitudinal TSPO lPET at 2.0 and 3.5 months of age.
All analyses were performed by PMOD (V3.5, PMOD technologies,
Basel, Switzerland). Normalization of injected activity was
performed by the previously validated myocardium correction
method (Deussing et al, 2018). TSPO lPET estimates (percentage
changes over time) deriving from a brainstem target VOI (7 mm³)
were extracted and compared descriptively between the two age
and genotype groups. Percentage difference maps were calculated
for the changes between baseline and follow-up for the averaged
images of Grn//Tmem106b/ and wild type.
Gene expression profiling and data analysis
Snap-frozen brain hemispheres were mechanically powdered in
liquid nitrogen. Following total RNA isolation with the Qiagen
RNeasy Mini Kit, 80 ng total RNA per sample was used for gene
◀ Figure 8. Enhanced TDP-43 aggregation and phosphorylation in Grn//Tmem106b/ mice.A Immunofluorescence analysis of TDP-43 in sagittal brain sections. Representative images of indicated brain regions (CTX, cortex; MB, midbrain). White arrow heads
indicate TDP-43 aggregation. Scale bar indicates 100 lm. Zoom in on TDP-43 aggregation in double knockout mouse brain sections of the midbrain, scale bar zoom
in indicates 50 lm (animals 4.5 months of age).
B Immunofluorescence analysis of total TDP-43 and phosphorylated TDP-43 (p-TDP-43) in sagittal brain sections by confocal microscopy. Representative images of one
confocal layer in the midbrain. Zoom in on TDP-43 aggregation in double knockout mouse brain sections of the midbrain. Scale bar indicates 25 lm (animals
4.5 months of age).
C Western blot analysis of TDP-43 and phosphorylated TDP-43 (p-TDP-43) in sequential high salt (HS)/RIPA/Urea fractionations of total brain lysates from 4.5-month-
old mice with the indicated genotype. Analysis of C-terminal fragments of TDP-43 (CTF) in RIPA fraction. p-TDP-43 analyzed in Urea fraction (n = 3 biological
replicates per genotype).
D Quantification of (C). Protein expression was normalized to levels in wild-type animals. Data represent the mean  SD.
Data information: For statistical analysis of normalized data (D), one-way ANOVA with Tukey’s post hoc test was used to compare individual genotypes. Significance is
indicated; ns P > 0.05; *P < 0.05; **P < 0.01.
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expression profiling with the nCounter Neuropathology panel from
NanoString (NanoString Technologies). Expression analysis on the
nCounter Neuroinflammation panel was conducted using 60 ng of
total RNA per sample. NanoString reads for all samples were
analyzed and normalized using the nSolver software including the R
plugin for advanced gene set analysis (NanoString Technologies).
The geometric mean of the on-chip housekeeping genes was used for
normalization of reads. The mean of each group was used for calcu-
lation of the fold changes. For the Neuropathology panel, each group
contained an n of three animals. The Neuroinflammation panel was
conducted on six wild-type, four Grn/ and four Tmem106b/single
knockout, and five double knockout Grn//Tmem106b/ mice.
Detailed information on mice used is listed in Table EV1. Volcano
plots were generated by plotting the log2-transformed changes
between wild-type and individual groups, against the calculated
values of significance with the software GraphPad Prism 8.
Western blotting and antibodies
Mice were PBS perfused, and for biochemically analysis, each brain
hemisphere was snap-frozen in liquid nitrogen and mechanically
ground to powder. Brain powder was lysed in RIPA buffer (150 mM
NaCl, 20 mM Tris–HCl pH 7.4, 1% NP40, 0.05% Triton X-100, 0.5%
sodium deoxycholate, 2.5 mM ETDA) using the Precellys lysing kit
(Ref.: P00933-LYSK0-A; Bertin Technologies). Supernatants were
collected after centrifugation at 17,000 g, 4°C, and protein concen-
tration was determined using the bicinchoninic acid assay (Inter-
chim Bioscience). For analysis of TDP-43 and p62, proteins were
sequentially isolated as described previously (Gotzl et al, 2014). All
samples were boiled in Laemmli buffer, and proteins were separated
on Tris-glycine gels. Proteins were transferred onto polyvinylidene
difluoride membranes or nitrocellulose membranes (both GE
Healthcare Life Science). HRP-conjugated antibodies and PierceTM
ECL Plus Western Blotting Substrate (Thermo Fisher Scientific) were
used for visualization. The following antibodies were used for
Western blotting: TMEM106B (clone 6F2, (Lang et al, 2012)), GFAP
(DAKO, Z0334), IBA1 (GeneTex, GTX100042), CD68 (Abcam,
ab125212), CLEC7A (R&D Systems, AF1756), TREM2 (clone 5F4,
(Xiang et al, 2016), p62 (MBL, PM045), LC3 (Novusbio, NB100),
Ubiquitin (Santa Cruz, clone P4D1), Cathepsin D (Santa Cruz, sc-
6486), Cathepsin B (R&D Systems, AF965), Cathepsin L (R&D
Systems, AF1515), TDP-43 (Proteintech, 12892-2AP), and Phospho-
TDP-43 409/410 (Cosmo Bio Co, CAC-TIP-PTD-M01).
Immunofluorescence and image acquisition
Following deep/lethal anesthesia, animals were PBS perfused. One
brain hemisphere was fixed overnight in 4% PFA in PBS (pH = 7.4)
and transferred to 30% sucrose in PBS. Brains were processed into
35-lm-thick sagittal sections. Sections were blocked in 4% goat
serum and incubated with indicated antibodies of the bellow listed
primary antibodies. After several washing steps, sections were incu-
bated with fluorophore conjugated secondary antibodies as indi-
cated (Alexa 488, 594, 647; Thermo Fisher Scientific). After
additional washing steps, nuclei were visualized with DAPI.
Sections were embedded in FluoromountTM (Sigma-Aldrich, Merck).
Image acquisition was performed on a LEICA DMI-8 with a
DFC9000GT camera and the following objectives: (HC PL FL L 20×/
0.40 CORR PH1; HC PL APO 40×/0.95 CORR). Confocal Images were
acquired on Zeiss LSM 800 Microscope Axio Observer 7 (Objective
Plan-Apochromat 63×/1,4 Oil M27). The following antibodies were
used for immunofluorescence: GFAP (DAKO, Z0334), IBA1
(GeneTex, GTX100042), CD68 (Abcam, ab125212), CLEC7A (R&D
Systems, AF1756), TREM2 (R&D Systems, AF1729), p62 (MBL,
PM045), p62 (Progen Biotech GP62C), NeuN (Millipore, MAB377),
TDP-43 (Proteintech, 12892-2AP), and Phospho-TDP-43 409/410
(Cosmo Bio Co, CAC-TIP-PTD-M01).
Enzyme activity assay
Fluorescence-based activity assays (Abnova) were used to asses
enzyme activity of cathepsin D, cathepsin B, and cathepsin L.
Mouse brain powder was homogenized in the recommended lysis
buffer and subsequently centrifuged. Cleavage of the quenched fluo-
rescence substrate was continuously measured using the Fluoroskan
Ascent FL plate reader (Labsystems).
Statistical analysis
Data were analyzed using GraphPad Prism 8. The rotarod perfor-
mance is displayed as mean duration on the rotarod from three
rounds of testing for each tested animal with standard deviation
(SD) of the respective group. Differences between groups were
tested by one-way ANOVA with Tukey’s post hoc test (Figs 1D, 4B,
5B, 6B and C, 7C and 8D). For the analysis of gene expression, the
mean of the individual group is compared to the mean of the wild-
type controls by two-tailed, unpaired Student’s t-test (Figs 2A–C
and 3A–C). For multiple comparison expression analysis and
enzyme activity, all data were normalized to wild type.
Significant differences are indicated as follows in all diagrams:
*P < 0.05; **P < 0.01; ***P < 0.001; and ****P < 0.0001.
Data availability
Data sets of raw and processed data produced in this study are avail-
able in the following database:
NanoString gene sequence, raw, and processed data:
Gene Expression Omnibus accession number (GSE155065) at
https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE155065
Gene Expression Omnibus accession number (GSE155066) at
https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE155066
Expanded View for this article is available online.
Acknowledgements
This work is supported by the Deutsche Forschungsgemeinschaft (DFG) within
the framework of the Munich Cluster for Systems Neurology (EXC 2145
SyNergy; ID 390857198). CH is supported by the Koselleck Project HA1737/16-1
of the DFG (Helmholtz-Gemeinschaft, Zukunftsthema “Immunology and
Inflammation” (ZT-0027)). We thank Ramona Rodde for excellent technical
assistance. We would like to acknowledge the NanoString EMEA grant
program for providing a Neuropathology panel. We would like to thank Dr. M.
Nishihara (Department of Veterinary Physiology, The University of Tokyo) for
providing the Grn/ founder mouse strain. Open access funding enabled and
organized by ProjektDEAL.
16 of 19 EMBO reports 21: e50241 | 2020 ª 2020 The Authors
EMBO reports Georg Werner et al
Author contributions
AC, CH, and GW conceived the study and analyzed the results. AC and CH
wrote the manuscript with input from all co-authors. GW performed all
Western blot assays and immunofluorescence experiments. DE conducted and
GW and MS performed behavioral experiments. MD performed the staining of
the spinal cord and provided support on immunofluorescence techniques. JG,
KW, and MB performed and analyzed TSPO-PET imaging. KF performed RNA
isolation and enzyme activity assays. WW consulted and BW generated the
Tmem106b/ founder mouse from ES cells.
Conflict of interest
CH collaborates with Denali Therapeutics, participated on one advisory board
meeting of Biogen, and received a speaker honorarium from Novartis and
Roche. CH is chief advisor of ISAR Bioscience.
References
Ahmed Z, Sheng H, Xu YF, Lin WL, Innes AE, Gass J, Yu X, Wuertzer CA, Hou
H, Chiba S et al (2010) Accelerated lipofuscinosis and ubiquitination in
granulin knockout mice suggest a role for progranulin in successful aging.
Am J Pathol 177: 311 – 324
Almeida MR, Macario MC, Ramos L, Baldeiras I, Ribeiro MH, Santana I (2016)
Portuguese family with the co-occurrence of frontotemporal lobar
degeneration and neuronal ceroid lipofuscinosis phenotypes due to
progranulin gene mutation. Neurobiol Aging 41: 200.e201 – 200
Arrant AE, Nicholson AM, Zhou X, Rademakers R, Roberson ED (2018) Partial
Tmem106b reduction does not correct abnormalities due to progranulin
haploinsufficiency. Mol Neurodegener 13: 32
Baker M, Mackenzie IR, Pickering-Brown SM, Gass J, Rademakers R, Lindholm
C, Snowden J, Adamson J, Sadovnick AD, Rollinson S et al (2006) Mutations
in progranulin cause tau-negative frontotemporal dementia linked to
chromosome 17. Nature 442: 916 – 919
Bateman A, Cheung ST, Bennett HPJ (2018) A brief overview of progranulin in
health and disease. Methods Mol Biol 1806: 3 – 15
Beel S, Moisse M, Damme M, De Muynck L, Robberecht W, Van Den Bosch L,
Saftig P, Van Damme P (2017) Progranulin functions as a cathepsin D
chaperone to stimulate axonal outgrowth in vivo. Hum Mol Genet 26:
2850 – 2863
Belcastro V, Siciliano V, Gregoretti F, Mithbaokar P, Dharmalingam G,
Berlingieri S, Iorio F, Oliva G, Polishchuck R, Brunetti-Pierri N et al (2011)
Transcriptional gene network inference from a massive dataset elucidates
transcriptome organization and gene function. Nucleic Acids Res 39:
8677 – 8688
van Blitterswijk M, Mullen B, Nicholson AM, Bieniek KF, Heckman MG, Baker
MC, DeJesus-Hernandez M, Finch NA, Brown PH, Murray ME et al (2014)
TMEM106B protects C9ORF72 expansion carriers against frontotemporal
dementia. Acta Neuropathol 127: 397 – 406
Brady OA, Zheng Y, Murphy K, Huang M, Hu F (2013) The frontotemporal
lobar degeneration risk factor, TMEM106B, regulates lysosomal
morphology and function. Hum Mol Genet 22: 685 – 695
Brendel M, Probst F, Jaworska A, Overhoff F, Korzhova V, Albert NL, Beck R,
Lindner S, Gildehaus FJ, Baumann K et al (2016) Glial activation and
glucose metabolism in a transgenic amyloid mouse model: a triple-tracer
PET study. J Nucl Med 57: 954 – 960
Capell A, Liebscher S, Fellerer K, Brouwers N, Willem M, Lammich S,
Gijselinck I, Bittner T, Carlson AM, Sasse F et al (2011) Rescue of
progranulin deficiency associated with frontotemporal lobar degeneration
by alkalizing reagents and inhibition of vacuolar ATPase. J Neurosci 31:
1885 – 1894
Chang MC, Srinivasan K, Friedman BA, Suto E, Modrusan Z, Lee WP, Kaminker
JS, Hansen DV, Sheng M (2017) Progranulin deficiency causes impairment
of autophagy and TDP-43 accumulation. J Exp Med 214: 2611 – 2628
Chen-Plotkin AS, Unger TL, Gallagher MD, Bill E, Kwong LK, Volpicelli-Daley
L, Busch JI, Akle S, Grossman M, Van Deerlin V et al (2012) TMEM106B,
the risk gene for frontotemporal dementia, is regulated by the
microRNA-132/212 cluster and affects progranulin pathways. J Neurosci
32: 11213 – 11227
Clayton EL, Milioto C, Muralidharan B, Norona FE, Edgar JR, Soriano A, Jafar-
Nejad P, Rigo F, Collinge J, Isaacs AM (2018) Frontotemporal dementia
causative CHMP2B impairs neuronal endolysosomal traffic-rescue by
TMEM106B knockdown. Brain 141: 3428 – 3442
Cruchaga C, Graff C, Chiang HH, Wang J, Hinrichs AL, Spiegel N, Bertelsen S,
Mayo K, Norton JB, Morris JC et al (2011) Association of TMEM106B gene
polymorphism with age at onset in granulin mutation carriers and
plasma granulin protein levels. Arch Neurol 68: 581 – 586
Cruts M, Gijselinck I, van der Zee J, Engelborghs S, Wils H, Pirici D,
Rademakers R, Vandenberghe R, Dermaut B, Martin JJ et al (2006) Null
mutations in progranulin cause ubiquitin-positive frontotemporal
dementia linked to chromosome 17q21. Nature 442: 920 – 924
DeJesus-Hernandez M, Mackenzie IR, Boeve BF, Boxer AL, Baker M, Rutherford
NJ, Nicholson AM, Finch NA, Flynn H, Adamson J et al (2011) Expanded
GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes
chromosome 9p-linked FTD and ALS. Neuron 72: 245 – 256
Deussing M, Blume T, Vomacka L, Mahler C, Focke C, Todica A, Unterrainer M,
Albert NL, Lindner S, von Ungern-Sternberg B et al (2018) Coupling
between physiological TSPO expression in brain and myocardium allows
stabilization of late-phase cerebral [(18)F]GE180 PET quantification.
NeuroImage 165: 83 – 91
Feng T, Mai S, Roscoe JM, Sheng RR, Ullah M, Zhang J, Iscol Katz I, Yu H,
Xiong W, Hu F (2020a) Loss of TMEM106B and PGRN leads to severe
lysosomal abnormalities and neurodegeneration in mice. EMBO Rep 21:
e50219
Feng T, Sheng RR, Sole-Domenech S, Ullah M, Zhou X, Mendoza CS, Enriquez
LCM, Katz II, Paushter DH, Sullivan PM et al (2020b) A role of the
frontotemporal lobar degeneration risk factor TMEM106B in myelination.
Brain 143: 2255 – 2271
Finch N, Carrasquillo MM, Baker M, Rutherford NJ, Coppola G, Dejesus-
Hernandez M, Crook R, Hunter T, Ghidoni R, Benussi L et al (2011)
TMEM106B regulates progranulin levels and the penetrance of FTLD in
GRN mutation carriers. Neurology 76: 467 – 474
Gallagher MD, Suh E, Grossman M, Elman L, McCluskey L, Van Swieten JC, Al-
Sarraj S, Neumann M, Gelpi E, Ghetti B et al (2014) TMEM106B is a
genetic modifier of frontotemporal lobar degeneration with C9orf72
hexanucleotide repeat expansions. Acta Neuropathol 127: 407 – 418
Gallagher MD, Posavi M, Huang P, Unger TL, Berlyand Y, Gruenewald AL,
Chesi A, Manduchi E, Wells AD, Grant SFA et al (2017) A dementia-
associated risk variant near TMEM106B alters chromatin architecture and
gene expression. Am J Hum Genet 101: 643 – 663
Gass J, Cannon A, Mackenzie IR, Boeve B, Baker M, Adamson J, Crook R,
Melquist S, Kuntz K, Petersen R et al (2006) Mutations in progranulin are
a major cause of ubiquitin-positive frontotemporal lobar degeneration.
Hum Mol Genet 15: 2988 – 3001
Ghoshal N, Dearborn JT, Wozniak DF, Cairns NJ (2012) Core features of
frontotemporal dementia recapitulated in progranulin knockout mice.
Neurobiol Dis 45: 395 – 408
ª 2020 The Authors EMBO reports 21: e50241 | 2020 17 of 19
Georg Werner et al EMBO reports
Gotzl JK, Mori K, Damme M, Fellerer K, Tahirovic S, Kleinberger G, Janssens J,
van der Zee J, Lang CM, Kremmer E et al (2014) Common
pathobiochemical hallmarks of progranulin-associated frontotemporal
lobar degeneration and neuronal ceroid lipofuscinosis. Acta Neuropathol
127: 845 – 860
Gotzl JK, Lang CM, Haass C, Capell A (2016) Impaired protein degradation in
FTLD and related disorders. Ageing Res Rev 32: 122 – 139
Gotzl JK, Colombo AV, Fellerer K, Reifschneider A, Werner G, Tahirovic S,
Haass C, Capell A (2018) Early lysosomal maturation deficits in microglia
triggers enhanced lysosomal activity in other brain cells of progranulin
knockout mice. Mol Neurodegener 13: 48
Gotzl JK, Brendel M, Werner G, Parhizkar S, Sebastian Monasor L, Kleinberger
G, Colombo AV, Deussing M, Wagner M, Winkelmann J et al (2019)
Opposite microglial activation stages upon loss of PGRN or TREM2 result
in reduced cerebral glucose metabolism. EMBO Mol Med 11: e9711
Guo A, Tapia L, Bamji SX, Cynader MS, Jia W (2010) Progranulin deficiency
leads to enhanced cell vulnerability and TDP-43 translocation in primary
neuronal cultures. Brain Res 1366: 1 – 8
Hara T, Nakamura K, Matsui M, Yamamoto A, Nakahara Y, Suzuki-Migishima
R, Yokoyama M, Mishima K, Saito I, Okano H et al (2006) Suppression of
basal autophagy in neural cells causes neurodegenerative disease in mice.
Nature 441: 885 – 889
Hardy J, Rogaeva E (2014) Motor neuron disease and frontotemporal
dementia: sometimes related, sometimes not. Exp Neurol 262(Pt B):
75 – 83
Hasegawa M, Arai T, Nonaka T, Kametani F, Yoshida M, Hashizume Y, Beach
TG, Buratti E, Baralle F, Morita M et al (2008) Phosphorylated TDP-43 in
frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Ann
Neurol 64: 60 – 70
Holler CJ, Taylor G, Deng Q, Kukar T (2017) Intracellular proteolysis of
progranulin generates stable, lysosomal granulins that are
haploinsufficient in patients with frontotemporal dementia caused by
GRN mutations. eNeuro 4: ENEURO.0100-17.2017
Hu F, Padukkavidana T, Vaegter CB, Brady OA, Zheng Y, Mackenzie IR,
Feldman HH, Nykjaer A, Strittmatter SM (2010) Sortilin-mediated
endocytosis determines levels of the frontotemporal dementia protein,
progranulin. Neuron 68: 654 – 667
Ikemoto S, Hamano SI, Kikuchi K, Koichihara R, Hirata Y, Matsuura R, Hiraide
T, Nakashima M, Inoue K, Kurosawa K et al (2020) A recurrent TMEM106B
mutation in hypomyelinating leukodystrophy: a rapid diagnostic assay.
Brain Dev 42: 603 – 606
Kao AW, McKay A, Singh PP, Brunet A, Huang EJ (2017) Progranulin, lysosomal
regulation and neurodegenerative disease. Nat Rev Neurosci 18: 325 – 333
Kayasuga Y, Chiba S, Suzuki M, Kikusui T, Matsuwaki T, Yamanouchi K, Kotaki
H, Horai R, Iwakura Y, Nishihara M (2007) Alteration of behavioural
phenotype in mice by targeted disruption of the progranulin gene. Behav
Brain Res 185: 110 – 118
Klein ZA, Takahashi H, Ma M, Stagi M, Zhou M, Lam TT, Strittmatter SM
(2017) Loss of TMEM106B ameliorates lysosomal and frontotemporal
dementia-related phenotypes in progranulin-deficient mice. Neuron 95:
281 – 296
Kleinberger G, Wils H, Ponsaerts P, Joris G, Timmermans JP, Van Broeckhoven
C, Kumar-Singh S (2010) Increased caspase activation and decreased TDP-
43 solubility in progranulin knockout cortical cultures. J Neurochem 115:
735 – 747
Kleinberger G, Capell A, Haass C, Van Broeckhoven C (2013) Mechanisms of
granulin deficiency: lessons from cellular and animal models. Mol
Neurobiol 47: 337 – 360
Komatsu M, Waguri S, Ueno T, Iwata J, Murata S, Tanida I, Ezaki J,
Mizushima N, Ohsumi Y, Uchiyama Y et al (2005) Impairment of
starvation-induced and constitutive autophagy in Atg7-deficient mice. J
Cell Biol 169: 425 – 434
Lang CM, Fellerer K, Schwenk BM, Kuhn PH, Kremmer E, Edbauer D,
Capell A, Haass C (2012) Membrane orientation and subcellular
localization of transmembrane protein 106B (TMEM106B), a major risk
factor for frontotemporal lobar degeneration. J Biol Chem 287:
19355 – 19365
Le NT, Chang L, Kovlyagina I, Georgiou P, Safren N, Braunstein KE, Kvarta MD,
Van Dyke AM, LeGates TA, Philips T et al (2016) Motor neuron disease,
TDP-43 pathology, and memory deficits in mice expressing ALS-FTD-linked
UBQLN2 mutations. Proc Natl Acad Sci USA 113: E7580 – E7589
Lee CW, Stankowski JN, Chew J, Cook CN, Lam YW, Almeida S, Carlomagno Y,
Lau KF, Prudencio M, Gao FB et al (2017) The lysosomal protein cathepsin
L is a progranulin protease. Mol Neurodegener 12: 55
Li Z, Farias FHG, Dube U, Del-Aguila JL, Mihindukulasuriya KA, Fernandez MV,
Ibanez L, Budde JP, Wang F, Lake AM et al (2020) The TMEM106B FTLD-
protective variant, rs1990621, is also associated with increased neuronal
proportion. Acta Neuropathol 139: 45 – 61
Liu Y, Pattamatta A, Zu T, Reid T, Bardhi O, Borchelt DR, Yachnis AT, Ranum
LP (2016) C9orf72 BAC mouse model with motor deficits and
neurodegenerative features of ALS/FTD. Neuron 90: 521 – 534
Lui H, Zhang J, Makinson SR, Cahill MK, Kelley KW, Huang HY, Shang Y,
Oldham MC, Martens LH, Gao F et al (2016) Progranulin deficiency
promotes circuit-specific synaptic pruning by microglia via complement
activation. Cell 165: 921 – 935
Luningschror P, Werner G, Stroobants S, Kakuta S, Dombert B, Sinske D,
Wanner R, Lullmann-Rauch R, Wefers B, Wurst W et al (2020) The
FTLD risk factor TMEM106B regulates the transport of lysosomes at
the axon initial segment of motoneurons. Cell Rep 30: 3506 –
3519
Murray ME, Cannon A, Graff-Radford NR, Liesinger AM, Rutherford NJ, Ross
OA, Duara R, Carrasquillo MM, Rademakers R, Dickson DW (2014)
Differential clinicopathologic and genetic features of late-onset amnestic
dementias. Acta Neuropathol 128: 411 – 421
Nelson PT, Wang WX, Partch AB, Monsell SE, Valladares O, Ellingson SR,
Wilfred BR, Naj AC, Wang LS, Kukull WA et al (2015) Reassessment of risk
genotypes (GRN, TMEM106B, and ABCC9 variants) associated with
hippocampal sclerosis of aging pathology. J Neuropathol Exp Neurol 74:
75 – 84
Neumann M, Kwong LK, Lee EB, Kremmer E, Flatley A, Xu Y, Forman MS,
Troost D, Kretzschmar HA, Trojanowski JQ et al (2009) Phosphorylation of
S409/410 of TDP-43 is a consistent feature in all sporadic and familial
forms of TDP-43 proteinopathies. Acta Neuropathol 117: 137 – 149
Nicholson AM, Finch NA, Wojtas A, Baker MC, Perkerson RB 3rd, Castanedes-
Casey M, Rousseau L, Benussi L, Binetti G, Ghidoni R et al (2013)
TMEM106B p. T185S regulates TMEM106B protein levels: implications for
frontotemporal dementia. J Neurochem 126: 781 – 791
Nicholson AM, Zhou X, Perkerson RB, Parsons TM, Chew J, Brooks M, DeJesus-
Hernandez M, Finch NA, Matchett BJ, Kurti A et al (2018) Loss of
Tmem106b is unable to ameliorate frontotemporal dementia-like
phenotypes in an AAV mouse model of C9ORF72-repeat induced toxicity.
Acta Neuropathol Commun 6: 42
Nixon RA (2013) The role of autophagy in neurodegenerative disease. Nat
Med 19: 983 – 997
Palmer DN, Barry LA, Tyynela J, Cooper JD (2013) NCL disease mechanisms.
Biochim Biophys Acta 1832: 1882 – 1893
EMBO reports Georg Werner et al
18 of 19 EMBO reports 21: e50241 | 2020 ª 2020 The Authors
Petkau TL, Neal SJ, Milnerwood A, Mew A, Hill AM, Orban P, Gregg J, Lu G,
Feldman HH, Mackenzie IR et al (2012) Synaptic dysfunction in
progranulin-deficient mice. Neurobiol Dis 45: 711 – 722
Petkau TL, Hill A, Leavitt BR (2016) Core neuropathological abnormalities in
progranulin-deficient mice are penetrant on multiple genetic backgrounds.
Neuroscience 315: 175 – 195
Ren Y, van Blitterswijk M, Allen M, Carrasquillo MM, Reddy JS, Wang X, Beach
TG, Dickson DW, Ertekin-Taner N, Asmann YW et al (2018) TMEM106B
haplotypes have distinct gene expression patterns in aged brain. Mol
Neurodegener 13: 35
Renton AE, Majounie E, Waite A, Simon-Sanchez J, Rollinson S, Gibbs JR,
Schymick JC, Laaksovirta H, van Swieten JC, Myllykangas L et al (2011) A
hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome
9p21-linked ALS-FTD. Neuron 72: 257 – 268
Rhinn H, Abeliovich A (2017) Differential aging analysis in human cerebral
cortex identifies variants in TMEM106B and GRN that regulate aging
phenotypes. Cell Syst 4: 404 – 415
Rutherford NJ, Carrasquillo MM, Li M, Bisceglio G, Menke J, Josephs KA, Parisi
JE, Petersen RC, Graff-Radford NR, Younkin SG et al (2012) TMEM106B risk
variant is implicated in the pathologic presentation of Alzheimer disease.
Neurology 79: 717 – 718
Sardiello M, Palmieri M, di Ronza A, Medina DL, Valenza M, Gennarino VA, Di
Malta C, Donaudy F, Embrione V, Polishchuk RS et al (2009) A gene network
regulating lysosomal biogenesis and function. Science 325: 473 –477
Schwenk BM, Lang CM, Hogl S, Tahirovic S, Orozco D, Rentzsch K,
Lichtenthaler SF, Hoogenraad CC, Capell A, Haass C et al (2014) The FTLD
risk factor TMEM106B and MAP6 control dendritic trafficking of
lysosomes. EMBO J 33: 450 –467
Settembre C, Ballabio A (2011) TFEB regulates autophagy: an integrated
coordination of cellular degradation and recycling processes. Autophagy 7:
1379 – 1381
Settembre C, Di Malta C, Polito VA, Garcia Arencibia M, Vetrini F, Erdin S,
Erdin SU, Huynh T, Medina D, Colella P et al (2011) TFEB links autophagy
to lysosomal biogenesis. Science 332: 1429 – 1433
Smith KR, Damiano J, Franceschetti S, Carpenter S, Canafoglia L, Morbin M,
Rossi G, Pareyson D, Mole SE, Staropoli JF et al (2012) Strikingly different
clinicopathological phenotypes determined by progranulin-mutation
dosage. Am J Hum Genet 90: 1102 – 1107
Snowden JS, Pickering-Brown SM, Mackenzie IR, Richardson AM, Varma A,
Neary D, Mann DM (2006) Progranulin gene mutations associated with
frontotemporal dementia and progressive non-fluent aphasia. Brain 129:
3091 – 3102
Stagi M, Klein ZA, Gould TJ, Bewersdorf J, Strittmatter SM (2014) Lysosome
size, motility and stress response regulated by fronto-temporal dementia
modifier TMEM106B. Mol Cell Neurosci 61: 226 – 240
Tanaka Y, Matsuwaki T, Yamanouchi K, Nishihara M (2013) Increased
lysosomal biogenesis in activated microglia and exacerbated neuronal
damage after traumatic brain injury in progranulin-deficient mice.
Neuroscience 250: 8 – 19
Tanaka Y, Chambers JK, Matsuwaki T, Yamanouchi K, Nishihara M (2014)
Possible involvement of lysosomal dysfunction in pathological changes of the
brain in aged progranulin-deficient mice. Acta Neuropathol Commun 2: 78
Tanaka Y, Suzuki G, Matsuwaki T, Hosokawa M, Serrano G, Beach TG,
Yamanouchi K, Hasegawa M, Nishihara M (2017) Progranulin regulates
lysosomal function and biogenesis through acidification of lysosomes.
Hum Mol Genet 26: 969 – 988
Van Deerlin VM, Sleiman PM, Martinez-Lage M, Chen-Plotkin A, Wang LS,
Graff-Radford NR, Dickson DW, Rademakers R, Boeve BF, Grossman M
et al (2010) Common variants at 7p21 are associated with
frontotemporal lobar degeneration with TDP-43 inclusions. Nat Genet 42:
234 – 239
Ward ME, Chen R, Huang HY, Ludwig C, Telpoukhovskaia M, Taubes A,
Boudin H, Minami SS, Reichert M, Albrecht P et al (2017) Individuals with
progranulin haploinsufficiency exhibit features of neuronal ceroid
lipofuscinosis. Sci Transl Med 9: eaah5642
Wils H, Kleinberger G, Janssens J, Pereson S, Joris G, Cuijt I, Smits V,
Ceuterick-de Groote C, Van Broeckhoven C, Kumar-Singh S (2010) TDP-43
transgenic mice develop spastic paralysis and neuronal inclusions
characteristic of ALS and frontotemporal lobar degeneration. Proc Natl
Acad Sci USA 107: 3858 – 3863
Wils H, Kleinberger G, Pereson S, Janssens J, Capell A, Van Dam D, Cuijt I, Joris
G, De Deyn PP, Haass C et al (2012) Cellular ageing, increased mortality
and FTLD-TDP-associated neuropathology in progranulin knockout mice. J
Pathol 228: 67 – 76
Xiang X, Werner G, Bohrmann B, Liesz A, Mazaheri F, Capell A, Feederle R,
Knuesel I, Kleinberger G, Haass C (2016) TREM2 deficiency reduces the
efficacy of immunotherapeutic amyloid clearance. EMBO Mol Med 8:
992 – 1004
Yin F, Banerjee R, Thomas B, Zhou P, Qian L, Jia T, Ma X, Ma Y, Iadecola C,
Beal MF et al (2010a) Exaggerated inflammation, impaired host defense,
and neuropathology in progranulin-deficient mice. J Exp Med 207:
117 – 128
Yin F, Dumont M, Banerjee R, Ma Y, Li H, Lin MT, Beal MF, Nathan C, Thomas
B, Ding A (2010b) Behavioral deficits and progressive neuropathology in
progranulin-deficient mice: a mouse model of frontotemporal dementia.
FASEB J 24: 4639 – 4647
Yu L, De Jager PL, Yang J, Trojanowski JQ, Bennett DA, Schneider JA (2015) The
TMEM106B locus and TDP-43 pathology in older persons without FTLD.
Neurology 84: 927 – 934
van der Zee J, Van Langenhove T, Kleinberger G, Sleegers K, Engelborghs S,
Vandenberghe R, Santens P, Van den Broeck M, Joris G, Brys J et al (2011)
TMEM106B is associated with frontotemporal lobar degeneration in a
clinically diagnosed patient cohort. Brain 134: 808 – 815
Zhou X, Sun L, Bastos de Oliveira F, Qi X, Brown WJ, Smolka MB, Sun Y, Hu F
(2015) Prosaposin facilitates sortilin-independent lysosomal trafficking of
progranulin. J Cell Biol 210: 991 – 1002
Zhou X, Paushter DH, Feng T, Pardon CM, Mendoza CS, Hu F (2017a)
Regulation of cathepsin D activity by the FTLD protein progranulin. Acta
Neuropathol 134: 151 – 153
Zhou X, Paushter DH, Feng T, Sun L, Reinheckel T, Hu F (2017b) Lysosomal
processing of progranulin. Mol Neurodegener 12: 62
Zhou X, Brooks M, Jiang P, Koga S, Zuberi AR, Baker MC, Parsons TM,
Castanedes-Casey M, Phillips V, Librero AL et al (2020a) Loss of
Tmem106b exacerbates FTLD pathologies and causes motor deficits in
progranulin deficient mice. EMBO Rep 21: e50197
Zhou X, Nicholson AM, Ren Y, Brooks M, Jiang P, Zuberi A, Phuoc HN,
Perkerson RB, Matchett B, Parsons TM et al (2020b) Loss of TMEM106B
leads to myelination deficits: implications for frontotemporal dementia
treatment strategies. Brain 143: 1905 – 1919
License: This is an open access article under the terms
of the Creative Commons Attribution-NonCommercial-
NoDerivs 4.0 License, which permits use and distribu-
tion in any medium, provided the original work is
properly cited, the use is non-commercial and no
modifications or adaptations are made.
Georg Werner et al EMBO reports
ª 2020 The Authors EMBO reports 21: e50241 | 2020 19 of 19
